Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BOLD
Upturn stock ratingUpturn stock rating

Boundless Bio, Inc. Common Stock (BOLD)

Upturn stock ratingUpturn stock rating
$1.07
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/03/2025: BOLD (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4 Target price
52w Low $1
Current$1.07
52w High $4.72

Analysis of Past Performance

Type Stock
Historic Profit -24.09%
Avg. Invested days 5
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 23.95M USD
Price to earnings Ratio 0.14
1Y Target Price 4
Price to earnings Ratio 0.14
1Y Target Price 4
Volume (30-day avg) 3
Beta -
52 Weeks Range 1.00 - 4.72
Updated Date 07/5/2025
52 Weeks Range 1.00 - 4.72
Updated Date 07/5/2025
Dividends yield (FY) -
Basic EPS (TTM) 7.71

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -29.89%
Return on Equity (TTM) -54.06%

Valuation

Trailing PE 0.14
Forward PE -
Enterprise Value -65726397
Price to Sales(TTM) -
Enterprise Value -65726397
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 22385600
Shares Floating 14281523
Shares Outstanding 22385600
Shares Floating 14281523
Percent Insiders 11.39
Percent Institutions 70.35

ai summary icon Upturn AI SWOT

Boundless Bio, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Boundless Bio, Inc. is a clinical-stage oncology company dedicated to revolutionizing cancer treatment through inhibition of extrachromosomal DNA (ecDNA). It was founded in 2018 and went public in 2024.

business area logo Core Business Areas

  • Oncology Drug Development: Focused on discovering and developing novel therapeutics that target ecDNA biology in cancer.

leadership logo Leadership and Structure

The leadership team comprises experienced individuals in oncology drug development and corporate management. The organizational structure is typical of a biotech company, with research, development, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • BBI-355: A novel, oral inhibitor of dihydroorotate dehydrogenase (DHODH) designed to selectively kill cancer cells harboring ecDNA. Currently in Phase 1/2 clinical trials. Competitors developing similar therapies include companies focused on novel oncology targets and DHODH inhibitors, though none specifically targeting ecDNA.

Market Dynamics

industry overview logo Industry Overview

The oncology drug development industry is highly competitive and rapidly evolving, with a significant unmet need for therapies targeting previously intractable cancers.

Positioning

Boundless Bio is positioned as a pioneer in the ecDNA-targeted therapy space, with a unique approach to addressing cancer driver genes found on ecDNA.

Total Addressable Market (TAM)

The TAM for oncology therapies is estimated in the hundreds of billions of dollars annually. Boundless Bio's success hinges on its ability to effectively target ecDNA in a subset of cancers, potentially capturing a significant portion of this TAM. Market reports estimate the oncology market at $200 billion+ USD.

Upturn SWOT Analysis

Strengths

  • First-mover advantage in ecDNA-targeted therapies
  • Strong intellectual property position
  • Experienced management team
  • Novel approach to cancer treatment

Weaknesses

  • Early-stage clinical development
  • High cash burn rate
  • Dependence on clinical trial success
  • Relatively small company size

Opportunities

  • Potential to address unmet needs in cancer treatment
  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline to other ecDNA-driven cancers
  • Positive clinical trial data

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • MRNA
  • LLY
  • GILD
  • AZN

Competitive Landscape

Boundless Bio is operating in a competitive landscape. Its competitive advantage lies in targeting ecDNA, but it faces competition from established oncology companies with broader pipelines and resources.

Growth Trajectory and Initiatives

Historical Growth: N/A - Relatively new company.

Future Projections: Future growth is heavily dependent on the success of BBI-355 and other pipeline candidates. Analyst estimates will likely emerge after more clinical data becomes available.

Recent Initiatives: Advancing BBI-355 through Phase 1/2 clinical trials, expanding research and development efforts.

Summary

Boundless Bio is a high-risk, high-reward biotech company pioneering a novel approach to cancer treatment. Its success hinges on clinical trial outcomes and securing further funding. Early data shows some promise, but competition from larger pharmaceutical companies is a significant risk. Positive clinical data should substantially increase the stock's value, whereas negative data may jeopardize its future.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Boundless Bio's website
  • SEC filings
  • ClinicalTrials.gov
  • Analyst reports (where available)
  • Company Press Releases

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investing in biotech companies involves significant risks. Market share values are approximate estimates.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Boundless Bio, Inc. Common Stock

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2024-03-28
CEO, President & Director Mr. Zachary Hornby
Sector Healthcare
Industry Biotechnology
Full time employees 64
Full time employees 64

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in preclinical models. In addition, the company offers ECHO, an ecDNA harboring oncogenes diagnostic test to detect ecDNA in patient tumor specimens; and Spyglass platform, a platform used to identify druggable targets in oncogene amplified cancers. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.